Psoriasis is a chronic inflammatory condition for which eleven FDA-approved biologic
therapies are approved. Over the past decade, studies have documented the higher efficacy …

Abstract Purpose: Interleukin (IL)-17 and IL-23 inhibitors are the newest biologic agents
used in the management of moderate-to-severe psoriasis. Active comparator studies allow …

Purpose Advances in the treatment of moderate-to-severe plaque psoriasis, including new
biological agents and related drugs, are reviewed. Summary Most patients with psoriasis …

The pathogenesis of psoriasis is unknown, although it is generally accepted that this chronic
inflammatory skin disorder is a complex autoimmune condition similar to other T-cell …

Background Real-life studies in psoriasis are lacking. Many monoclonal antibodies targeting
tumor-necrosis factor (TNF)-alpha, interleukin 17, and 23 are approved drugs for psoriasis …

Psoriasis is a common inflammatory skin disease with multiple comorbidities, including
psoriatic arthritis and coronary artery disease, that can severely impact an individual's …

Psoriasis (PsO) is a common, systemic, chronic inflammatory disease characterized by key
clinical symptoms, including itching, pain, and scaling, and is associated with substantial …

The emergence of data from clinical trials of biologics, the approval of new biologics, and
our improved understanding of psoriasis pathogenesis have increased the therapeutic …

Introduction: The cytokines interleukin (IL)-12 and IL-23 have been involved in the
pathogenesis of psoriasis and psoriatic arthritis. Ustekinumab is a fully human monoclonal …

Background: Psoriasis is a chronic immune-mediated inflammatory skin disorder that is
estimated to affect 2-3% of the general population. The IL-23/IL-17 axis is currently …